Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 23, 2020 (Event Date)
Reporting Period: Single event disclosure regarding a material definitive agreement.
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, or margins) as it is a current report on a specific corporate event. However, it outlines the following financial obligations and conditions:
- Condition Precedent: The license agreement is contingent upon the Company closing an equity offering with at least $15 million in gross proceeds and successfully up-listing to Nasdaq by October 30, 2020.
- Upfront Consideration: Upon satisfaction of conditions, the Company must pay $100,000 in cash and issue 500,000 shares of common stock (subject to adjustment if the offering price is below $8.34 per share).
- Milestone Payments: Future payments include development/regulatory milestones (cash and stock) and sales milestones based on annual thresholds.
- Royalties: Ongoing royalties based on annual licensing sales.
Material Changes
The primary material change is the entry into an exclusive License Agreement with Elion Oncology, Inc. for the global development, manufacture, and commercialization of the asset PCS6422. This represents a strategic shift to acquire new intellectual property contingent on capital raising and market listing status.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company is required to use commercially reasonable efforts to research, develop, and commercialize the product. Specific diligence milestones include:
- Dosing a first patient in a Phase 1B clinical trial within 12 months.
- Dosing a first patient in a Phase 2 or 3 clinical trial within 48 months.
- Financing Risk: The agreement is void if the Company fails to raise $15 million or up-list to Nasdaq by October 30, 2020.
- Dilution Risk: Issuance of 500,000 shares (plus potential adjustments) and future milestone shares will dilute existing shareholders.
- Termination Risk: Either party may terminate for material breach (90-day cure period, reduced to 15 days for payment breaches).
- Sub-licensing: The Company must share milestone payments received from sub-licensees with Elion.
Investor Verification Checklist
- Verify if the Company successfully closed the required $15 million equity offering.
- Confirm the Company's up-listing status to Nasdaq by the October 30, 2020 deadline.
- Review the full text of the License Agreement (Exhibit 10.1) for specific milestone payment amounts and royalty rates not detailed in the summary.
- Monitor the Company's cash burn rate to ensure it can fund the required diligence milestones (Phase 1B within 12 months).
- Check for any subsequent filings regarding the issuance of the 500,000 shares to Elion Oncology.